Details of the Drug Reposition

General Information of This Drug (ID: DMMWZET)

Drug Name
Dexamethasone   DMMWZET
Synonyms
Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
44 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Serum sickness DIS0MRKJ N.A. Approved [1]
Rheumatic heart disease DISCI8JQ N.A. Approved [1]
Primary cutaneous T-cell lymphoma DIS35WVW N.A. Approved [1]
Miliary tuberculosis DIS4AT5W N.A. Approved [1]
Malignant otitis externa caused by Pseudomonas aeruginosa DIS5C8KP N.A. Approved [1]
Keratitis DISMFOEI N.A. Approved [1]
Granuloma annulare DISMOUMI N.A. Approved [1]
Exanthem DISAFOQN N.A. Approved [1]
Erythema multiforme DISKCLM1 N.A. Approved [1]
Epicondylitis DIS0R2VM N.A. Approved [1]
Disorder of orbital region DISH0ECJ N.A. Approved [1]
Diamond-Blackfan anemia DISI2SNW N.A. Approved [1]
Central retinal vein occlusion with macular edema DISKBNZP N.A. Approved [1]
Bursitis DISCF7Y9 N.A. Approved [1]
Burkitt lymphoma DIS9D5XU N.A. Approved [1]
Blepharoconjunctivitis DIS4PG4J N.A. Approved [1]
Allergic otitis media DIS97RHR N.A. Approved [1]
Acute adrenal insufficiency DIS66YLV N.A. Approved [1]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Approved [2]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Mycosis fungoides DIS62RB8 2B01 Approved [1]
Lung cancer DISCM4YA 2C25.0 Approved [1]
Autoimmune haemolytic anaemia DIS7MS3M 3A20 Approved [1]
Angioedema DIS90QDN 4A00.15 Approved [1]
Systemic lupus erythematosus DISI1SZ7 4A40.0 Approved [1]
Sarcoidosis DISE5B8Z 4B20.5 Approved [1]
Congenital adrenal hyperplasia DISG873W 5A71.01 Approved [1]
Addison disease DIS7HNOH 5A74.0 Approved [1]
Multiple sclerosis DISB2WZI 8A40 Approved [1]
Cerebral edema DIS4GHSB 8D60.1 Approved [1]
Corneal ulcer DIS8YN8N 9A76 Approved [1]
Allergic rhinitis DIS3U9HN CA08.0 Approved [1]
Acute asthma DISGYB62 CA23 Approved [1]
Liver cirrhosis DIS4G1GX DB93.1 Approved [1]
Crohn disease DIS2C5Q8 DD70 Approved [1]
Inflammatory bowel disease DISGN23E DD72 Approved [1]
Skin disease DISDW8R6 EA00-EM0Z Approved [1]
Psoriasis DIS59VMN EA90 Approved [1]
Dermatitis herpetiformis DIS0TC0G EB44 Approved [1]
Rosacea DIS02PWG ED90.0 Approved [1]
Psoriatic arthritis DISLWTG2 FA21 Approved [1]
Articular cartilage disorder DIS9LQVD FA34.Y Approved [1]
Vomiting DISDOA71 MD90 Approved [1]
Corneal abrasion DIS3SD7J NA06.4 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 44 Indications(s)
2 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pemphigus DISZAZ6M N.A. Withdrawn [3]
Allergic conjunctivitis DISZ5ZJN 9A60.02 Withdrawn [4]
------------------------------------------------------------------------------------
5 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Tenosynovitis DISR5H9R N.A. Discontinued in Phase 3 [5]
Nephrotic syndrome DISSPSC2 N.A. Discontinued in Phase 3 [6]
Otitis externa DISYCORK AA00-AA13 Discontinued in Phase 3 [7]
Seborrhoeic dermatitis DISNWVJU EA81 Discontinued in Phase 3 [8]
Contact dermatitis DISQ3AU0 EK0Z Discontinued in Phase 3 [9]
------------------------------------------------------------------------------------
10 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Thyroiditis DISTCV24 N.A. Discontinued in Phase 2 [10]
Iritis DISSA7AC N.A. Discontinued in Phase 2 [11]
Humoral hypercalcemia of malignancy DISQQ62D N.A. Discontinued in Phase 2 [12]
Exfoliative dermatitis DISQEWIW N.A. Discontinued in Phase 2 [13]
Leukemia DISNAKFL N.A. Discontinued in Phase 2 [14]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 2 [15]
Anterior uveitis DISQ7EAD 9A96 Discontinued in Phase 2 [16]
Atopic dermatitis DISTCP41 EA80 Discontinued in Phase 2 [17]
Arthritis DIST1YEL FA20 Discontinued in Phase 2 [18]
Ankylosing spondylitis DISRC6IR FA92.0 Discontinued in Phase 2 [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Indications(s)
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Discontinued in Phase 1 [20]
Musculoskeletal disorder DISPPN0O FA00-FC0Z Discontinued in Phase 1 [21]
------------------------------------------------------------------------------------
8 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Trichinellosis DISUR2ZW N.A. Investigative [1]
Iridocyclitis DISV6UP4 N.A. Investigative [1]
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [1]
Beta-thalassemia major DISW06BV N.A. Investigative [1]
B-cell neoplasm DISVY326 N.A. Investigative [1]
Acquired thrombocytopenia DISXH01C N.A. Investigative [1]
Follicular lymphoma DISVEUR6 2A80 Investigative [1]
Keloid DISV09JY EE60 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)

References

1 Dexamethasone FDA Label
2 Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17. doi: 10.1056/NEJMoa2021436.
3 Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D
4 QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
5 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
6 Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients
7 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
8 Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone
9 Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
10 A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
11 Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
12 Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
13 Efficacy and Safety Study of Ammonul in Patients With Grade 3 or 4 Hepatic Encephalopathy
14 Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
15 S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
16 Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
17 Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
18 Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer
19 Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
20 ClinicalTrials.gov (NCT00096005) Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
21 Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas